A Phase II Study to Evaluate Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis-- A Double-Blind, Placebo-Controlled, Randomized Controlled Trial
A Study Evaluating Abatacept (Orencia) for Treatment of Systemic Sclerosis
Sponsor: University of Michigan and Bristol-Myers Squibb
Enrolling: Male and Female Patients
Study Length: 1 Years
Clinic Visits: 7
IRB Number: AAAO3551
U.S. Govt. ID: NCT02161406
Contact: Afshin Zartoshti MSc: 212-342-2751 / az2200@cumc.columbia.edu
Additional Study Information: Systemic sclerosis (SSc) is a systemic connective tissue disease characterized by fibrosis and atrophy, namely of the skin, internal organs, joints, and skeletal muscles. This is a double-blind, placebo-controlled trial to test the efficacy of abatacept (Orencia) on the treatment of diffuse cutaneous systemic sclerosis in patients with a disease duration of 36 months.
This study is closed
Elana Bernstein, MD
Do You Qualify?
Have you been diagnosed with diffuse cutaneous systemic sclerosis (dcSSc)? Yes No
Was your first non-Raynaud manifestation of dcSSc within the last 3 years? Yes No
Do you have pulmonary arterial hypertension? Yes No
Do you have a history of organ transplantation? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Afshin Zartoshti MSc